17. SAFETY, TOXICITY, AND ADVERSE EVENTS 17.1 Toxicity associated with Standard Therapy (HDC + PBSCT) HDC + PBSCT is an aggressive chemotherapeutic regimen that is standard therapy in this patient population at our Center and worldwide. The significant toxicities associated with this treatment are universal , with 99% of all patient s experiencing Grade 3 or greater treatment related toxicity within the first 100 days post HDC. In order to assess any potential toxicity’s associated with DC + xALT therapy we have classified toxicity evaluation into three possible categories: 1) Non-overlapping toxicities 2) Immunotherapy related mortality 3) Chemotherapy related toxicity For ease of surveying common toxicities associated with this treatment regimen (or similar high -dose chemotherapy regimen s) in patients with reMB/PNETs a table of toxicities experienced in three representative Toxicity ( Grade 3, 4) Gururangan et al. 1998 Broniscer et al.